Journal
The New England Journal of Medicine
Publication Date
2018
Volume
378
Issue
4
Inclusive Pages
331-344
Document Type
Open Access Publication
DOI
10.1056/NEJMoa1708984
Rights and Permissions
Connors, J. M.; Jurczak, W.; Straus, D. J.; Ansell, S. M.; Kim, W. S.; Gallamini, A.; Younes, A.; Alekseev, S.; Illes, A.; Picardi, M.; Lech-Maranda, E.; Oki, Y.; Feldman, T.; Smolewski, P.; Savage, K. J.; Bartlett, N. L.; Walewski, J.; Chen, R.; Ramchandren, R.; Zinzani, P. L.; Cunningham, D.; Rosta, A.; Josephson, N. C.; Song, E.; Sachs, J.; Liu, R.; Jolin, H. A.; Huebner, D.; Radford, J. (2018). Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. The New England Journal of Medicine, 378 (4), 331-344. DOI: 10.1056/NEJMoa1708984. http://www.nejm.org/doi/full/10.1056/NEJMoa1708984. Copyright © 2017 Massachusetts Medical Society.
Recommended Citation
Bartlett, N. L. and et al, "Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma." The New England Journal of Medicine. 378, 4. 331-344. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/6532
